🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

Novo Nordisk, Eli Lilly stock slides after Biden op-ed calls for lower Ozempic, Wegovy Prices

Published 07/02/2024, 09:12 AM
Updated 07/02/2024, 09:14 AM
© Reuters.  Novo Nordisk, Eli Lilly stock slides after Biden op-ed calls for lower Ozempic, Wegovy Prices
LLY
-
NVO
-

Shares of Eli Lilly & Co. (NYSE:LLY) and Novo Nordisk (NYSE:NVO) fell by more than 2% and 3%, respectively, premarket Tuesday after U.S. President Joe Biden said Novo Nordisk must cut Ozempic and Wegovy prices.

Biden and Senator Bernie Sanders called on the company to cut prices of its weight loss and diabetes drugs in an editorial published in USA Today on Tuesday.

"If Novo Nordisk and other pharmaceutical companies refuse to substantially lower prescription drug prices in our country and end their greed, we will do everything within our power to end it for them," they state in the article.

Biden and Sanders said they have long had concerns regarding the "outrageous prices" the pharmaceutical industry charges American people for prescription drugs.

They also said they plan to expand negotiations on drug prices: "The number of prescription drugs up for price negotiation must be expanded to at least 50 a year. We are working together on legislation to do just that."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.